STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $170,602 | -62.9% | 43,300 | 0.0% | 0.00% | – |
| Q2 2023 | $460,279 | +62.0% | 43,300 | +27.0% | 0.00% | – |
| Q1 2023 | $284,053 | -17.3% | 34,100 | -8.3% | 0.00% | – |
| Q4 2022 | $343,356 | -28.2% | 37,200 | 0.0% | 0.00% | – |
| Q3 2022 | $478,000 | +3.9% | 37,200 | +6.9% | 0.00% | – |
| Q2 2022 | $460,000 | -28.3% | 34,800 | +14.1% | 0.00% | – |
| Q1 2022 | $642,000 | -5.2% | 30,500 | +8.2% | 0.00% | – |
| Q4 2021 | $677,000 | -5.6% | 28,200 | 0.0% | 0.00% | – |
| Q3 2021 | $717,000 | -24.4% | 28,200 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $949,000 | +18.6% | 28,200 | +36.9% | 0.00% | 0.0% |
| Q1 2021 | $800,000 | -31.3% | 20,600 | +9.6% | 0.00% | 0.0% |
| Q4 2020 | $1,164,000 | +58.8% | 18,800 | -14.2% | 0.00% | 0.0% |
| Q3 2020 | $733,000 | +40.4% | 21,900 | 0.0% | 0.00% | – |
| Q2 2020 | $522,000 | +46.2% | 21,900 | +40.4% | 0.00% | – |
| Q1 2020 | $357,000 | -19.2% | 15,600 | 0.0% | 0.00% | – |
| Q4 2019 | $442,000 | – | 15,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |